Continue to Expect a Limited Role for PCSK9 Inhibitors

May 2017

You'll hear buzz about using the PCSK9 inhibitors, Repatha (evolocumab) or Praluent (alirocumab), in patients with CV disease.

These injectable meds lower LDL cholesterol by about 60%...but we've been waiting to see if they improve CV outcomes.

Now evidence suggests that adding Repatha to a statin in patients with CV disease and other risks (diabetes, etc) prevents one more CV event for every 74 patients treated for about 2 years.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cholesterol Continue to Expect a Limited Role for PCSK9 Inhibitors
Pregnancy Watch for Oral Antibiotics to Avoid During Pregnancy
Oral Health Don't Use Antibiotic Prophylaxis Prior to Dental Procedures for Most Patients
HIV & AIDS Know What to Watch for With Complex Regimens in Hospitalized HIV Patients
Gastroenterology Steer Clear of Viberzi in Patients Who Don't Have a Gallbladder
Back Pain Don't Rely on Acetaminophen for Chronic Low Back Pain
Antithrombotics Consider Anticoagulants After Intracranial Hemorrhage in Some A Fib Patients
Overactive Bladder Put the Efficacy and Safety of Overactive Bladder Meds Into Perspective
Respiratory & Allergy Help Patients Know the Differences Among OTC Oral Antihistamines
Cardiology Don't Rely on Fish Oil Supplements to Reduce CV Risk
Rosacea Save Rhofade or Mirvaso for Rosacea Patients With Persistent Facial Redness

Continue to Expect a Limited Role for PCSK9 Inhibitors

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents